TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.
TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.